About this Journal Submit a Manuscript Table of Contents

Enhanced Cardiovascular Risk in Rheumatoid Arthritis: Elucidation, Assessment, and Management

Call for Papers

Patients with rheumatoid arthritis (RA) experience a substantially increased risk for cardiovascular disease and mortality. High-grade systemic inflammation in RA can modify conventional cardiovascular risk factor profiles as well as directly enhance atherogenesis. However, the molecular mechanisms underlying the systemic inflammation-cardiovascular risk relation in RA have not been fully identified. Also, the contribution of disease characteristics including inflammation and their interactions with conventional cardiovascular risk factors to enhanced cardiovascular risk in RA awaits clear delineation. Finally, most of our knowledge on cardiovascular risk in RA originates in studies that were performed in developed and predominantly white populations whereas the majority of cardiovascular events presently occur in developing populations.

Congruent with these unresolved issues, recently reported evidence indicates that the application of current recommendations on cardiovascular risk stratification in RA may result in a large proportion of patients at high risk of cardiovascular disease remaining unidentified and consequently receiving inadequate preventive intervention. We are therefore interested in original manuscripts including review papers that explore cardiovascular risk in RA. Potential topics include, but are not limited to:

  • Novel cardiovascular risk factors including biomarkers in RA
  • Genetic polymorphisms associated with cardiovascular risk in RA
  • Impact of ethnicity on cardiovascular risk in RA
  • Alterations in cardiovascular risk factor profiles in RA
  • Interactions between RA characteristics and conventional risk factors and their role in enhanced cardiovascular risk
  • The use of surrogate markers of cardiovascular risk including subclinical atherosclerosis in RA
  • Impact of antirheumatic agents on cardiovascular risk in RA
  • Impact of cardiovascular drugs on cardiovascular risk in RA
  • Cardiovascular preventive measures and outcome in patients with RA

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/cdi/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/rheumatology/ecr/ according to the following timetable:

Manuscript DueFriday, 5 September 2014
First Round of ReviewsFriday, 28 November 2014
Publication DateFriday, 23 January 2015

Lead Guest Editor

  • Patrick H. Dessein, Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Guest Editors

  • Anne G. Semb, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
  • Miguel A. Gonzalez-Gay, Department of Rheumatology, Hospital Universitario Marques de Valdecilla, IFIMAV, Avenida de Valdecilla S/N, 39008 Santander, Spain
  • Calin D. Popa, Department of Rheumatology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands